Akums launches Lasmiditan Tablet for migraine management

Akums Drugs & Pharmaceuticals has launched the Lasmiditan tablet. This medication has received approvals from the Drug Controller General of India (DCGI) and the United States Food and Drug Administration (USFDA).

Lasmiditan belongs to the “selective serotonin receptor agonists” class of medications and is specifically designed to alleviate the symptoms associated with migraine headaches.

The medication is formulated to interrupt pain signals to the brain and address nerve inflammation contributing to migraine symptoms. Each film-coated tablet of Lasmiditan contains lasmiditan hemisuccinate 57.824 mg/115.65 mg eq. to Lasmiditan 50mg/100mg. By binding with the 5-HT1F receptor, Lasmiditan presents an avenue for migraine relief.

A company statement informed, “Lasmiditan offers a recommended dosage of 50 mg to 100 mg, taken orally as needed. Notably, only one dose is advised within a 24-hour period. Lasmiditan’s high central nervous system penetration ensures a more targeted approach to migraine management. Importantly, the medication aims to reduce migraine pain and alleviate bothersome symptoms within two hours of a single dose, without the vasoconstriction side effects. Lasmiditan works on a specific type of Serotonin receptor found not on blood vessels but on nerves that are responsible for transmitting the pain of headache.”